Patient-Derived Protein Aggregate Seeding in Cell Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately replicate the formation of insoluble aggregates associated with neurodegenerative diseases in cultured cells, as aggregates formed in vitro differ from those in patient brains, and there is a limited amount of insoluble aggregates available from patients for analysis.
Innovation Solution
A method involving introducing an insoluble fraction from a neurodegenerative disease patient's brain into cultured cells expressing neurodegenerative-disease-related proteins, followed by incubation and separation of insoluble fractions, with the option to repeat this process for amplification, to produce homogeneous insoluble aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insoluble aggregates from patient brains are used directly for analysis, then the authenticity of the aggregates is ensured, but the amount available is limited
Solution Approach 1:
The patent applies preliminary action by pre-preparing and storing insoluble aggregate fractions from patient brains before they are needed for experiments. These pre-prepared aggregates are then introduced into cultured cells to initiate aggregation, allowing researchers to obtain large quantities of homogeneous aggregates without needing to collect extensive patient samples each time.
Solution Approach 2:
The patent uses patient-derived insoluble aggregates as templates or seeds to generate copies of the same aggregates in cultured cells. By introducing the authentic patient aggregates into cells expressing the relevant protein, the system replicates the aggregation process, producing large amounts of homogeneous aggregates that mirror the original patient samples.
2Ease of manufacture
If proteins are merely transiently expressed in cells, then the experimental procedure is simple, but no aggregates similar to patient brain inclusions are formed
Solution Approach 1:
The patent introduces insoluble aggregate fractions from patient brains as an intermediary element that mediates the aggregation process in cultured cells. This intermediary provides the necessary nucleation seeds that trigger and guide the formation of authentic aggregates, bridging the gap between simple protein expression and accurate aggregate formation without requiring complex transfection procedures.
Solution Approach 2:
By introducing patient-derived aggregates as seeds, the system copies the authentic aggregation process that occurs in patient brains. This copying mechanism ensures that the aggregates formed in cultured cells accurately replicate the structure, composition, and properties of patient brain inclusions, achieving high manufacturing precision while maintaining procedural simplicity.
3Ease of operation
If aggregates are formed in vitro using current methods, then the process is controllable, but the resulting aggregates differ from those in patient brains
Solution Approach 1:
The patent uses insoluble aggregate fractions from patient brains as an intermediary that transfers the authentic aggregation characteristics to the in vitro system. This intermediary ensures that the aggregates formed in controlled cell culture conditions faithfully reproduce the patient brain aggregates, maintaining reliability while preserving ease of operation through standard cell culture techniques.
Solution Approach 2:
The patent changes the key parameter of aggregate nucleation by introducing pre-formed patient aggregates instead of relying on spontaneous aggregation. This parameter change allows the system to maintain full controllability of the cell culture process while ensuring the resulting aggregates are identical to those in patient brains, as the patient aggregates serve as templates that dictate the aggregation outcome.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the production of large amounts of homogeneous insoluble aggregates, enabling detailed analysis and the development of therapeutic agents by mimicking the aggregation process, thereby facilitating the study and treatment of neurodegenerative diseases.
Implementation Method 1
new aggregates are formed when the aggregates of the proteins prepared in vitro are introduced into the cells and then act as a nucleus i.e. seed of the aggregation
Data Source
Figure 1-1~1-2
Figure 1-3
Figure 2-1~2-2
AI summary
The purpose of the present invention is to develop a method for producing a large amount of an insoluble aggregate that is equivalent to an insoluble aggregate formed in the brain of a patient. A method of producing an insoluble aggregate of a neurodegenerative-disease-related protein according to the present invention comprises the steps of: (1) introducing an insoluble fraction originated from the brain of a neurodegenerative disease patient into a cultured cell in which the neurodegenerative-disease-related protein can be expressed in a constitutive manner; (2) culturing the cultured cell into which the insoluble fraction has been introduced; and (3) extracting separating an insoluble fraction from the cultured cell. Optionally, the method may additionally comprise a step of amplifying the insoluble aggregate of the neurodegenerative-disease-related protein in the cultured cell.